RxDoctor Payments Data

Martha Leen, MD

Ophthalmology · Silverdale, WANPI 1093716458

Payments from drug & device makers

$2,250in general payments, 2019–2025

Across 74 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$595
  • AbbVie$587
  • Sight Sciences, Inc.$155
  • Apellis Pharmaceuticals, Inc.$118
  • Bausch & Lomb Americas Inc.$103
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$93
  • plus $600 from 14 others

What the payments were for

  • Speaking & faculty fees$1004%
  • Food & beverage$2,15096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,250 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$473,061
Medicare patients
833
Services billed
4,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate80$38,446
RestasisCyclosporine25$35,335
LumiganBimatoprost36$22,619
VyzultaLatanoprostene Bunod24$15,742
RocklatanNetarsudil Mesylat/Latanoprost22$13,136
Travoprost91$12,609
SimbrinzaBrinzolamide/Brimonidine Tart32$10,489
Latanoprost705$9,731
Brinzolamide53$8,944
CombiganBrimonidine Tartrate/Timolol15$8,869
Prednisolone Acetate194$8,369
Timolol Maleate308$8,261
Alphagan PBrimonidine Tartrate13$7,351
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat287$5,431
Brimonidine Tartrate195$5,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$587$74,17489 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$14$51,582102 claims
Bausch & Lomb Americas Inc.Vyzulta$103$15,74224 claims
AlconSimbrinza$595$10,48932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →